Just months after deadlocking, the U.S. Federal Trade Commission voted unanimously on Tuesday to launch an investigation into pharmacy benefit managers’ business practices to assess their impact on prescription drug access and affordability.
Groups that represent 340B health care providers told the commission during a recent public comment period that PBMs’ discriminatory policies hurt the providers’ missions to serve vulnerable patients.
Just months after deadlocking, the U.S. Federal Trade Commission on Tuesday voted unanimously on Tuesday to launch an investigation into pharmacy benefit managers’ business practices to assess their impact on prescription drug access and affordability.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
